Takeda Pharmaceuticals announced that it has enrolled the first patient in its registry established to gather data on patients with Crohn’s disease with complex fistulas treated with Alofisel.

Known as the INSPIRE registry, the database is a non-interventional, open-enrollment registry that Takeda says will help further understanding of the long-term effectiveness of Alofisel (darvadstrocel) in terms of clinical remission, health care use and health-related quality of life for patients. The registry will collect data using validated indices and patient-reported outcomes.

The first patient, who lives in Austria, will be joined by approximately 1,600 other patients taken from countries where Alofisel is currently available.

Takeda Pharmaceuticals announced that it has enrolled the first patient in its registry established to gather data on patients with Crohn’s disease with complex fistulas treated with Alofisel.

Known as the INSPIRE registry, the database is a non-interventional, open-enrollment registry that Takeda says will help further understanding of the long-term effectiveness of Alofisel (darvadstrocel) in terms of clinical remission, health care use and health-related quality of life for patients. The registry will collect data using validated indices and patient-reported outcomes.

The first patient, who lives in Austria, will be joined by approximately 1,600 other patients taken from countries where Alofisel is currently available.